Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cardiology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cardiology Other
    The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials - (BMJ)
    FDA Approves Dronedarone for Atrial Fibrillation or Atrial Flutter - (DGNews)
    Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease - (JAMA)
    Novel and conventional biomarkers for prediction of incident cardiovascular events in the community - (JAMA)
    Kidney function and risk of cardiovascular disease and mortality in women: a prospective cohort study - (BMJ)

    News archive

     Recent webcasts/CME - Cardiology Other
    • State of the Science in Managing the Treatment-Experienced Patient With HIV
    • What's New in Managing Treatment-Experienced Patients With HIV?
    • Applying Data to Practice: Case Vignettes
    • Rheumatoid Arthritis: The Heart of the Matter Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis
      Supraventricular Tachycardia in Children and Adolescents

      Webcasts/CME archive

       Recent cases - Cardiology Other
        Cardiogenic Shock Caused by Disulfiram
        Congenital Atresia of the Left Main Coronary Artery Associated With Patent Ductus Arteriosus and Aortic Regurgitation
        Pleural Effusion and Pulmonary Hypertension in a Patient With Parkinson Disease Treated With Cabergoline
        A Well-Circumscribed Density Along the Right Heart Border
        A Case of Massive Pulmonary Embolism with ST Elevation in Leads V1-4

        Cases archive
          




        my personal edition > cardiology other > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Pre-treatment With Acetylcysteine For Cardiac Catheterisation Reduces Contrast-Induced Nephropathy

        A DGReview of :"Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography"
        Catheterization and Cardiovascular Interventions

        12/05/2003
        By Mohammad Ahmad, MD


        Prophylactic administration of acetylcysteine reduces the development of contrast-induced nephropathy in patients with mild to moderate renal dysfunction prior to coronary angiography, say American researchers.

        Contrast-induced nephropathy (CIN) is an important cause of acute renal failure in patients undergoing cardiac catheterisation. Prehydration and the use of low-osmolality contrast agents may prevent CIN. Evidence suggests that the use of acetylcysteine reduces the incidence of CIN in patients undergoing computed tomography (CT).

        In a randomised, double blind trial, Briain D. MacNeill, MD, and colleagues from the Cardiology Division, Massachusetts General Hospital and Harvard Medical School in Boston, United States, examined the prophylactic efficacy of acetylcysteine in decreasing the incidence of CIN in elderly patients with mild to moderate renal insufficiency.

        Researchers defined mild to moderate renal dysfunction as a serum creatinine (Cr) >/= 1.5 mg/dL while CIN was defined as a rise in serum creatinine of > 25% from baseline. Prior to cardiac catheterisation, all patients were treated with 0.45% saline at a rate of 1 mL/kg/hr for 12 hr for in-patients and 2 mL/kg/hr for 4 hr for day-case patients. Serum creatinine and urea were measured before and at 24, 48, and 72 hours after the procedure.

        Twenty-one patients were randomised to 600 mg of acetylcysteine, and 22 patients to placebo. Each group received 2 doses - first at the time of randomisation, followed by the second dose 4 hours later. Catheterisation was carried out with non-ionic contrast agents (iopromide or ioxilan). The patients received 3 additional doses of acetylcysteine 600 mg or placebo at 12-hr intervals after the catheterisation. All patients received post catheterisation hydration with 0.45% saline at 75 mL/hr for 12 hr.

        The results show no significant difference in baseline renal function between patients receiving acetylcysteine, or placebo. The serum creatinine levels remained unchanged in the acetylcysteine group (1.89 ± 0.38 at baseline to 1.90 ± 0.36 mg/dL at 72 hr) compared to the placebo (1.90 ± 0.36 at baseline to 2.38 ± 1.19 mg/dL at 72 hr).

        By the 72 hours, CIN occurred in 1 out of 21 patients put on acetylcysteine compared to 7 of 22) patients in the placebo group (P = .046).

        No adverse effect was observed in patients receiving acetylcysteine treatment. Serum creatinine levels at 48 and 72 hours remained constant in the acetylcysteine group but continued to rise at 48 and 72 hours in the placebo group.

        The authors noted that CIN is a significant iatrogenic complication with profound effects on patient morbidity and mortality. Pre-existing renal dysfunction, particularly diabetic nephropathy, and advanced age may predispose to CIN.

        The researchers concluded that the cumulative effect of the data from the present and earlier studies along with the safe pharmacological profile and relatively low cost of acetylcysteine tilts the balance further towards the uses of acetylcysteine in mild to moderate renal dysfunction patients undergoing cardiac catheterisation.

        Cathet Cardiovasc Intervent 2003;60:4:458-461. "Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send